Arca BioPharma hopeful about personalized beta blocker

07/28/2008 | American City Business Journals

Arca BioPharma is inching closer to launching bucindolol, an experimental beta blocker that would be the first genetically targeted heart-failure drug. The biotech firm intends to file this week for FDA approval of the drug along with a genetic test being developed by partner Lab Corp.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR